Form Type: 4

SEC EDGAR Link
Acccession Number:0001179110-20-005307
Date:2020-04-28
Issuer: THERAVANCE BIOPHARMA, INC. (TBPH)
Original Submission Date:

Reporting Person:

YOUNG WILLIAM D
C/O THERAVANCE BIOPHARMA US, INC.
901 GATEWAY BOULEVARD SOUTH SAN FRANCISCO, CA 94080

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
ORDINARY SHARES 2020-04-28 A 6,635 a $0.00 58,330 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
SHARE OPTION (RIGHT TO BUY) 30.14 2020-04-28 deemed execution date A 6,000 (a) 2030-04-27 ordinary shares 6,000 $30.14 6,000 direct
Footnotes
IDfootnote
f1 this option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.

Elevate your investments